Venclax 100 mg (Tablet)
Unit Price: ৳ 600.00 (5 x 6: ৳ 18,000.00)
Strip Price: ৳ 3,600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Venetoclax |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Treatment of chronic lymphocytic leukemia (CLL)
- Indicated for patients with 17p deletion or TP53 mutation
- Indicated for patients who have failed chemoimmunotherapy
- Indicated for patients who have failed B-cell receptor pathway inhibitor
Pharmacology
- Selective and orally bioavailable small-molecule inhibitor of BCL-2
- Restores the process of apoptosis
- Cytotoxic activity in tumor cells that overexpress BCL-2
Dosage & Administration
- Starting dose of 20 mg once daily for 7 days
- Gradual increase to a daily dose of 400 mg over 5 weeks
- Continued treatment for 24 months in combination with Rituximab
Interaction
- Contraindicated with strong CYP3A inhibitors
- Avoid concomitant use with moderate CYP3A inhibitors
- Avoid concomitant use with P-gp and BCRP inhibitors
Contraindications
- Hypersensitivity to the active substance or excipients
- Concomitant use of strong CYP3A inhibitors
- Concomitant use of St. John's wort preparations
Side Effects
- Neutropenia
- Diarrhoea
- Upper respiratory tract infection
- Nausea
- Anaemia
- Fatigue
- Pneumonia
- Febrile neutropenia
Pregnancy & Lactation
- Women of childbearing potential must use highly effective contraception
- Not recommended during pregnancy
- Discontinue breastfeeding during treatment
Precautions & Warnings
- Tumour lysis syndrome risk
- Neutropenia monitoring and management
- Avoid immunization with live attenuated vaccines
- Avoid concomitant use with CYP3A4 inducers
- Highly effective contraception recommended for women of childbearing potential
Use in Special Populations
- No specific dose adjustment for elderly patients
- No dose adjustment for mild or moderate renal impairment
- Increased risk of TLS in patients with reduced renal function
- No dose adjustment for mild or moderate hepatic impairment
- Recommended dose reduction for severe hepatic impairment
- Safety and efficacy not established in pediatric population
Overdose Effects
- No specific antidote
- Careful monitoring and supportive treatment
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Store below 30°C
- Protect from moisture and light